ストックスクリーナーアプリを入手
3.3195
1.08%
-0.0405
前日終値:
$3.36
開ける：
$3.36
24時間の取引高:
2.01M
Relative Volume:
0.55
時価総額：
$403.83M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-9.117
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
-0.49%
1か月 パフォーマンス:
-44.23%
6か月 パフォーマンス:
-16.28%
1年 パフォーマンス:
+5.85%
1日の値動き範囲:
$3.31
$3.42
1週間の範囲:
$3.155
$3.55
52週間の値動き範囲:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.31 | 409.93M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
123.92 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.26 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.63 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.59 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Jim Cramer on Aquestive Therapeutics: “I’m Not Sure If They Deserve the Benefit of the Doubt” - Insider Monkey
AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
How does Aquestive Therapeutics Inc. score in quality rankingsWeekly Loss Report & Technical Confirmation Alerts - bollywoodhelpline.com
Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge Due to FDA Concerns - Intellectia AI
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Shorts Report: Is Aquestive Therapeutics Inc backed by strong institutional buyingQuarterly Investment Review & Verified Technical Trade Signals - baoquankhu1.vn
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations - NewMediaWire
About Us - FinancialContent
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc.AQST - PR Newswire
A Look At Aquestive Therapeutics (AQST) Valuation After Anaphylm Regulatory Update And FDA Feedback - Sahm
Commonwealth Equity Services LLC Takes $5.92 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now - sharewise.com
Rate Hike: Is Aquestive Therapeutics Inc gaining market share2025 Price Momentum & Low Drawdown Trading Strategies - baoquankhu1.vn
Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST) - marketscreener.com
Trend Review: How does Aquestive Therapeutics Inc score in quality rankingsJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation - TradingView — Track All Markets
Aquestive drops as FDA flags issues in Anaphylm marketing application - MSN
Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle - Seeking Alpha
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround - Yahoo Finance
Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm FilingWhat's Changed - Sahm
Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies - Yahoo Finance
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks making the biggest moves today - MSN
Why Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies In Anaphylm Application – And What's Next - Yahoo Finance
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet - Benzinga
AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed - Stocktwits
Sector Update: Health Care - MarketScreener
Aquestive Therapeutics Stock Dips Amid Financial Challenges - StocksToTrade
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC - GlobeNewswire
Is Aquestive Therapeutics Inc. stock oversold or undervalued2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aquestive Therapeutics Sees Unusually Large Options Volume (NASDAQ:AQST) - MarketBeat
FDA Identifies NDA Deficiencies for Anaphylm as Review Continues, Aquestive Therapeutics Announces - Patient Care Online
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies ... - Bluefield Daily Telegraph
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
Aquestive Therapeutics Inc (AQST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
3.10 |
25,000 |
77,568 |
308,346 |
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Sale |
7.01 |
67,575 |
473,701 |
240,771 |
| Kraus Carl N | Chief Medical Officer |
Oct 15 '25 |
Sale |
7.00 |
20,272 |
141,904 |
282,475 |
| Boyd Peter E. | See Remarks |
Oct 15 '25 |
Sale |
7.00 |
10,000 |
70,000 |
268,323 |
3.43%
大文字化:
|
ボリューム (24 時間):